Colliers Securities started coverage on shares of Legend Biotech (NASDAQ:LTRN) in a report published on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $24.00 target price on the stock.
LTRN opened at $12.32 on Tuesday. Legend Biotech has a 1-year low of $11.51 and a 1-year high of $15.44.
About Legend Biotech
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.